New Zealand markets closed
  • NZX 50

    11,137.88
    -19.78 (-0.18%)
     
  • NZD/USD

    0.6345
    +0.0034 (+0.55%)
     
  • ALL ORDS

    7,350.60
    +24.40 (+0.33%)
     
  • OIL

    113.96
    -0.24 (-0.21%)
     
  • GOLD

    1,825.20
    +11.20 (+0.62%)
     

Worldwide Plasma Fractionation Industry to 2028 - Rising Application of Plasma Therapy is Driving Growth - ResearchAndMarkets.com

·3-min read

DUBLIN, January 24, 2022--(BUSINESS WIRE)--The "Plasma Fractionation Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

The plasma fractionation market is projected to reach US$ 40,731.98 million by 2028 from US$ 26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% during 2021-2028.

The market growth is mainly attributed to the rising application of plasma therapy and active participation of companies in market developments. However, the availability of recombinant or non-plasma counterparts. Further, development potential in emerging countries offers lucrative opportunities for the growth of the plasma fractionation market.

As stated in the previous driver, the market offers considerable potential for the companies operating the market-related businesses. Due to the positive market growth, the global and regional market players are actively adopting organic and inorganic development strategies. Thus it is expected to attract more significant investments in the market in the forecast period. For instance, below are some of the developments and initiatives adopted by the market players.

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, and other applications. The neurology segment is expected to hold the largest share of the market in 2021 and is expected to register the highest CAGR during the forecast period. The plasma fractionation market, by product, is segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and other plasma products. The immunoglobulin segment is estimated to hold the largest share of the market in 2021, and it is further expected to register the highest CAGR in the market during 2021-2028.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the plasma fractionation market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global plasma fractionation market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Market Dynamics

Drivers

  • Rising Application of Plasma Therapy

  • Active Participation of the Players in Market Developments

Restraints

  • Availability of Non-Plasma Substitutes

Opportunities

  • Development Potential in Emerging Countries

Future Trends

  • Use of Plasma Therapy for Treating Novel Diseases

Companies Mentioned

  • Biotest AG.

  • Octapharma AG

  • Kedrion S.p.A

  • CSL Limited

  • Grifols, S.A.

  • Bio Products Laboratory Ltd.

  • Sanquin

  • Bharat Serums and Vaccines Limited (BSV)

  • SK Plasma

  • PlasmaGen BioSciences Pvt. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ijyakr

View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005604/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting